Immune recovery and T cell subset analysis during effective treatment with maraviroc

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2474-2478

  Cossarini, Francesca ^a,b   Galli, Andrea ^a   Galli, Laura ^a   Bigoloni, Alba ^a   Salpietro, Stefania ^a   Vinci, Concetta ^a   Della torre, Liviana ^a   Gianotti, Nicola ^a   Spagnuolo, Vincenzo ^a,b   Lazzarin, Adriano ^a,b   Castagna, Antonella ^a   Nozza, Silvia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

CCR5; CXCR4; Darunavir; HIV; Immune activation; Maraviroc; Naive T cells

Indexed keywords

A 4001050; CHEMOKINE RECEPTOR CXCR4; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; MARAVIROC; RALTEGRAVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOHEXANES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; RECEPTORS, CCR5; RECEPTORS, CXCR4; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84866628548     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks216     Document Type: Article

References (13)

1. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010; 201: 803-13.
2. Asmuth DM, Goodrich J, Cooper DA et al. CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 2010; 54: 394-7.
3. Saag M, Goodrich J, Fatkenheuer G et al. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 2009; 199: 1638-47.
4. Nakanjako D, Ssewanyana I, Mayanja-Kizza H et al. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis 2011; 11: 43.
5. Hunt PW, Martin JN, Sinclair E et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-43.
6. Mussini C, Pinti M, Borghi V et al. Features of 'CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS 2002; 16: 1609-16.
7. Delobel P, Sandres-Saune K, Cazabat M et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2005; 38: 382-92.
8. Funderburg N, Kalinowska M, Eason J et al. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One 2010; 5: e13188.
9. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDS cohort study. Clin Immunol Immunopathol 1989; 52: 10-8.
10. Di Mascio M, Sereti I, Matthews LT et al. Naive T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 2006; 80: 2665-74.
11. Pitrak DL, Estes R, Novak RM et al. Beneficial effects of a switch to a lopinavir/ritonavir-containing regimen for patients with partial or no immune reconstitution with highly active antiretroviral therapy despite complete viral suppression. AIDS Res Hum Retroviruses 2011; 27: 659-67.
12. Rossi R, Lichtner M, De Rosa A et al. In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells. Clin Exp Immunol 2011; 166: 184-90.
13. Fiser AL, Vincent T, Brieu N et al. High CD4+ T-cell surface CXCR4 density as a risk factor for R5 to X4 switch in the course of HIV-1 infection. J Acquir Immune Defic Syndr 2010; 55: 529-35